This comprehensive cancer panel interrogates relevant cancer biomarkers with as little as 20-30 ng of cfDNA and demonstrates robust analytical performance. In addition to variant calls, the assay reports a tumor mutational burden (TMB) score and microsatellite instability (MSI) status. Available now as an RUO offering at our genomics center of excellence in North Carolina, USA.
Enhanced algorithm to robustly call TMB from cfDNA. Reports include a synonymous and non- synonymous score using eligible variants that meet the following criteria:
Sample Types | Plasma (EDTA, Streck or purified circulating-free nucleic acids) |
Sample Recommendations | > 3 mL plasma (minimum 2 mL plasma) Double-spun EDTA within 4 hr of collection OR Streck cfDNA BCT extends stability window to 6 days @ RT |
Input Requirements | 20-30 ng cfDNA (as quantified using Fragment Analyzer) |
Sequencing Platform | NovaSeq 6000 |
Read Depth | > 400 M PE Reads; 150bp PE |
Software Analysis | Illumina’s Early Access TSO500 Plasma pipeline for ctDNA analysis |
Deliverables | QC Report, VCFs (SNVs and Indels), CNVs, MSI and TMB scores BAMs can be made available upon request for additional fee |
The TruSight Oncology 500 (TSO500) ctDNA assay employs a hybrid capture-based approach targeting 523 clinically relevant genes and leverages unique molecular indices to enable ultra-low frequency...
Measurement of minimal residual disease (MRD) is one of the best predictors of treatment outcome for leukemia, lymphoma and myeloma.Two approaches of specific interest due to the innovation they...
Author: Victor Weigman, Ph.D., Associate Director, Associate Director, Translational Genomics, Q2 SolutionsThe excitement surrounding immuno-oncology (I-O) is being driven by results seen in the...